LBA53 Sintilimab plus chemotherapy (chemo) versus chemo as first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (ORIENT-16): First results of a randomized, double-blind, phase III study

Jianming Xu, Hong Jiang, Yueyin Pan, Kangsheng Gu, Shundong Cang, Li Han, Yongqian Shu, J. Li, Jiuda Zhao, Hongming Pan, Suxia Luo, Yanru Qin, Qianshuang Guo, Yu Bai, Ling Ye, Yanchun Guo, Z. Li, Yuntong liu, Y. Wang, H. Zhou